IRIS UniCatt

Laurenti, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.432
AS - Asia 10.847
EU - Europa 10.070
SA - Sud America 2.424
AF - Africa 324
OC - Oceania 187
Continente sconosciuto - Info sul continente non disponibili 17
Totale 38.301
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.999
SG - Singapore 4.913
CN - Cina 2.661
DE - Germania 2.567
BR - Brasile 1.972
SE - Svezia 1.739
IT - Italia 1.632
VN - Vietnam 983
FR - Francia 931
UA - Ucraina 701
GB - Regno Unito 602
IE - Irlanda 540
IN - India 484
ID - Indonesia 373
FI - Finlandia 340
RU - Federazione Russa 272
JP - Giappone 254
CA - Canada 231
AR - Argentina 189
HK - Hong Kong 183
TR - Turchia 168
AU - Australia 157
BD - Bangladesh 150
PL - Polonia 139
MX - Messico 127
IQ - Iraq 110
NL - Olanda 104
KR - Corea 87
ZA - Sudafrica 79
AT - Austria 70
ES - Italia 65
SA - Arabia Saudita 62
EC - Ecuador 57
PK - Pakistan 50
BE - Belgio 47
CO - Colombia 47
CI - Costa d'Avorio 46
MA - Marocco 46
UZ - Uzbekistan 45
VE - Venezuela 41
EG - Egitto 39
CH - Svizzera 36
CZ - Repubblica Ceca 33
PY - Paraguay 33
CL - Cile 31
NZ - Nuova Zelanda 30
HU - Ungheria 29
IR - Iran 29
RO - Romania 29
JO - Giordania 28
IL - Israele 27
KE - Kenya 27
PH - Filippine 25
NP - Nepal 24
DZ - Algeria 23
LT - Lituania 22
AE - Emirati Arabi Uniti 21
TH - Thailandia 20
BG - Bulgaria 19
MY - Malesia 19
PE - Perù 19
GR - Grecia 18
LB - Libano 17
PT - Portogallo 17
AZ - Azerbaigian 16
BO - Bolivia 16
UY - Uruguay 15
ET - Etiopia 13
OM - Oman 13
NO - Norvegia 12
RS - Serbia 12
DO - Repubblica Dominicana 11
JM - Giamaica 11
KZ - Kazakistan 11
AL - Albania 10
HR - Croazia 10
LK - Sri Lanka 10
SK - Slovacchia (Repubblica Slovacca) 10
TN - Tunisia 10
BA - Bosnia-Erzegovina 9
MD - Moldavia 9
QA - Qatar 8
SI - Slovenia 8
TT - Trinidad e Tobago 8
CR - Costa Rica 7
HN - Honduras 7
KG - Kirghizistan 7
SN - Senegal 7
AO - Angola 6
DK - Danimarca 6
EU - Europa 6
KW - Kuwait 6
LV - Lettonia 6
NI - Nicaragua 6
PA - Panama 6
TW - Taiwan 6
XK - ???statistics.table.value.countryCode.XK??? 6
AM - Armenia 5
BY - Bielorussia 5
BZ - Belize 5
Totale 38.197
Salva come PNG Salva come JPEG
Città #
Singapore 2.480
Chandler 1.394
Ashburn 1.323
San Jose 1.162
Beijing 561
Dublin 521
Jacksonville 421
San Mateo 355
Los Angeles 351
Jakarta 327
Ho Chi Minh City 315
Lauterbourg 315
Dearborn 304
Nanjing 299
New York 289
Wilmington 272
Hanoi 254
Rome 253
Milan 251
Hefei 249
Tokyo 223
Ann Arbor 219
Boston 199
Council Bluffs 197
Munich 188
Frankfurt am Main 185
Hyderabad 179
Dallas 178
Florence 175
Cattolica 170
Hong Kong 164
Chicago 160
São Paulo 154
Houston 150
Woodbridge 146
Redwood City 140
Moscow 139
Lawrence 133
Seattle 133
Buffalo 126
Princeton 126
Nanchang 122
Nürnberg 121
Redmond 111
Marseille 108
Helsinki 107
Lancaster 107
Fairfield 96
Warsaw 93
Izmir 85
Orem 82
Kunming 81
Santa Clara 80
Bremen 78
Boardman 77
Seoul 74
The Dalles 74
Rio de Janeiro 69
Tianjin 67
London 66
Brooklyn 64
Kent 61
Phoenix 60
Paris 59
Atlanta 56
Mountain View 56
Shenyang 54
Shanghai 52
Guangzhou 51
Lappeenranta 48
Norwalk 48
Washington 47
Abidjan 46
San Francisco 46
Nuremberg 45
Zhengzhou 45
Belo Horizonte 44
Da Nang 44
Brussels 43
Stockholm 42
Toronto 42
Düsseldorf 41
Tashkent 41
Haiphong 39
Hangzhou 39
Pune 39
Baghdad 38
Cambridge 38
Chennai 38
Hebei 38
Porto Alegre 38
Montreal 37
Sydney 37
Johannesburg 36
Turku 36
Vienna 36
Jiaxing 35
Mexico City 35
Philadelphia 35
Denver 34
Totale 18.641
Salva come PNG Salva come JPEG
Nome #
VITAMIN B12 DEFICIENCY: CORRELATION BETWEEN MTHFR POLYMORPHISMS AND CLINICAL AND LABORATORY FINDINGS 3.260
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 659
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 431
Factors associated with mortality in bacteremic patients with hematologic malignancies. 374
Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis 371
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 331
Prospective study of hepatitis B virus reactivation in patients with hematological malignancies 224
Factors associated with mortality in bacteremic patients with hematologic malignancies. 218
Correlation between paraproteinaemia and viral reactivation after allo-SCT 215
Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. 214
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome 209
Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation 201
Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma. A pilot study. 194
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. 187
Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy 179
Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients 177
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 176
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 175
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 174
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation 171
Role of (18)F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients 169
New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia 168
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia 168
All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients 166
The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia. Leukemia. 165
Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab. 164
Work related acute leukemia and mucor mycosis in a boat-builder 162
Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. 161
Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: Safety and efficacy evaluation. 160
Hyperleukocytosis and leukostasis: management of a medical emergency 159
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation 156
Role of microRNAs in Chronic Lymphocytic Leukemia 155
Neurologic improvement after peripheral blood stem cell transplantation in poems 155
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS 155
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication 155
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. 155
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 154
Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy 153
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration 152
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 151
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 150
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 150
Usefulness of F-18 FDG PET/CT in the follow-up of POEMS syndrome after autologous peripheral blood stem cell transplantation 149
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 149
AB0 type does not affect platelet engraftment after autologous peripheral blood stem cell transplant in a series of 249 hematologic patients 148
Light chain deposition in peripheral nerve as a cause of mononeuritis multiplex in Waldenström's macroglobulinaemia. 147
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia 147
H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016 147
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 147
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 146
Hyperleukocytosis and leukostasis: management of a medical emergency 146
Granulocyte transfusions as adjunctive treatment of invasive fungal diseases in neutropenic patients 144
TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients 144
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 144
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 143
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine 141
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 141
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 141
Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study 141
The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia 138
Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience 138
Mycosis fungoides as a cause of severe obstructive sleep apnea 137
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 137
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T 136
Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome 136
Non-tunnelled central venous catheters in adult stem cell transplantation recipients: an effective option 135
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 133
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 133
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 132
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 131
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 130
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 130
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 128
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 127
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 127
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 126
Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity 125
Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia 125
Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. 123
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 123
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 123
The Syk kinase as a therapeutic target in leukemia and lymphoma 122
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease 122
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease 122
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 122
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 122
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 121
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. 121
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 121
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 121
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 120
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 120
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. 120
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 119
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells 118
Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients 117
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 117
Cd200 baseline serum levels predict prognosis of chronic lymphocytic leukemia 117
Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion 117
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study 116
Totale 19.236
Salva come PNG Salva come JPEG
Categoria #
all - tutte 157.191
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 157.191
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021423 0 0 0 0 0 0 0 0 0 65 317 41
2021/20222.251 184 131 127 152 167 65 38 321 106 126 427 407
2022/20234.402 628 625 350 539 332 552 196 305 500 85 212 78
2023/20244.020 126 725 199 775 221 499 193 110 131 231 384 426
2024/20256.361 377 275 505 244 483 201 191 300 821 701 1.307 956
2025/202613.609 2.219 509 1.015 1.629 2.287 831 2.265 843 1.022 989 0 0
Totale 38.831